Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD

Introduction: LAMAs reduce the severity of daily symptoms such as dyspnoea. The potential impact of LAMAs on the physical activity (PA), sedentary time (ST) and sleep of people living with COPD is unclear. Aim: To determine changes in PA, ST and sleep after starting LAMA therapy versus usual care. Methods: Patients with moderate-severe COPD were recruited and randomised to 6 weeks of LAMA or Usual Care (UC) (or PR). SenseWear-derived steps, ST (≤1.5METs), light PA (>1.5 Results: Data from 33 patients in the LAMA group and 14 in Control group (70% male, age 67±8 years, 51% GOLD II) were analysed. No changes in PA, ST or SD were observed for either group (Fig 1). LAMA group experienced no change in NDSB whilst controls increased NDSB (LAMA: 1.2±1.4 versus 1.1±1.5 NDSB and UC: 0.7±0.9 versus 1.8±1.7 NDSB; interaction p=0.018) with no other changes in sleep outcomes. Conclusion: A six-week LAMA intervention reduced the NDSB but did not change time spent in 24-hour physical behaviours or other sleep quality outcomes.